{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:29:46Z","timestamp":1794018586245,"version":"4.8.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"41","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"am","delay-in-days":393,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007338","name":"All-India Institute of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019501","name":"Universidad Peruana Cayetano Heredia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008700","name":"Centre International de Recherche sur le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009647","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009647","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007229","name":"Harvard University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007229","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001506","name":"Ministry of Science and Innovation, New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001506","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-021904"],"award-info":[{"award-number":["INV-021904"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004421","name":"World Bank Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004421","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016195","name":"United Nations Development Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016195","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006641","name":"UNICEF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006641","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007112","name":"University of Cape Town","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007112","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007812","name":"University of Washington","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006661","name":"United Nations Population Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018788","name":"Veterinary Clinical Sciences Department, College of Veterinary Medicine, University of Minnesota","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018788","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.vaccine.2022.08.020","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T08:12:53Z","timestamp":1661155973000},"page":"5843-5855","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021\u2014March 2022"],"prefix":"10.1016","volume":"40","author":[{"given":"Holly J.","family":"Prudden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon L.","family":"Achilles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celina","family":"Schocken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Broutet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Canfell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Akaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partha","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neerja","family":"Bhatla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z. Mike","family":"Chirenje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinead","family":"Delany-Moretlwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynette","family":"Denny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa G.","family":"Gamage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolando","family":"Herrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Hutubessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa Lina","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Murillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Stanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"Temmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanghui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Ogilvie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Kaslow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami L","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.vaccine.2022.08.020_b0005","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1080\/01443615.2019.1634030","article-title":"Human papillomavirus and cervical cancer","volume":"40","author":"Okunade","year":"2020","journal-title":"J Obstetr Gynaecol: J Inst Obstetr Gynaecol"},{"issue":"3","key":"10.1016\/j.vaccine.2022.08.020_b0010","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer J Clin [Internet]"},{"key":"10.1016\/j.vaccine.2022.08.020_b0015","unstructured":"The World Health Organisation. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva; 2020."},{"issue":"10224","key":"10.1016\/j.vaccine.2022.08.020_b0020","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0140-6736(20)30068-4","article-title":"Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries","volume":"395","author":"Brisson","year":"2020","journal-title":"Lancet [Internet]"},{"key":"10.1016\/j.vaccine.2022.08.020_b0025","article-title":"The Full Value of Vaccine Assessments (FVVA): a framework to assess and communicate the value of vaccines for investment and introduction decision making. social science research","author":"Hutubessy","year":"2021","journal-title":"Network"},{"issue":"8","key":"10.1016\/j.vaccine.2022.08.020_b9000","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S2214-109X(22)00241-8","article-title":"Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis","volume":"10","author":"Bruni","year":"2022","journal-title":"Lancet Glob Health."},{"key":"10.1016\/j.vaccine.2022.08.020_b0030","unstructured":"The World Health Organisation. WHO Preferred Product Characteristics (PPCs) [Internet]; 2022 [cited 2022 Jan 28]. <https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/product-and-delivery-research\/ppcs>."},{"issue":"11","key":"10.1016\/j.vaccine.2022.08.020_b0035","doi-asserted-by":"crossref","first-page":"e79260","DOI":"10.1371\/journal.pone.0079260","article-title":"Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study","volume":"8","author":"Jaisamrarn","year":"2013","journal-title":"PLoS One [Internet]"},{"issue":"3","key":"10.1016\/j.vaccine.2022.08.020_b0040","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ajog.2012.09.007","article-title":"Human papillomavirus: what every provider should know","volume":"208","author":"Erickson","year":"2013","journal-title":"Am J Obstet Gynecol [Internet]"},{"key":"10.1016\/j.vaccine.2022.08.020_b0045","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.34128","article-title":"Different human papillomavirus types share early natural history transitions in immunocompetent women","author":"Adebamowo","year":"2022","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.vaccine.2022.08.020_b0050","first-page":"485","article-title":"The natural history of type-specific human papillomavirus infections in female university students","volume":"12","author":"Richardson","year":"2003","journal-title":"Cancer Epidemiol Biomark Prevent: Publ Am Assoc Cancer Res, Cosponsor Am Soc Prevent Oncol"},{"key":"10.1016\/j.vaccine.2022.08.020_b0055","unstructured":"The World Health Organisation. Cervical Cancer."},{"key":"10.1016\/j.vaccine.2022.08.020_b0060","unstructured":"UK Health Security. Human papillomavirus (HPV): the green book, chapter 18a; 2019."},{"key":"10.1016\/j.vaccine.2022.08.020_b0065","unstructured":"National Cancer Institute. Study Identifies Crucial Characteristic of High-Risk HPV. 2017."},{"issue":"2","key":"10.1016\/j.vaccine.2022.08.020_b0075","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S2214-109X(20)30459-9","article-title":"Estimates of the global burden of cervical cancer associated with HIV","volume":"9","author":"Stelzle","year":"2021","journal-title":"Lancet Global Health [Internet]"},{"issue":"15","key":"10.1016\/j.vaccine.2022.08.020_b0080","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1001\/jama.2020.16244","article-title":"Lifetime prevalence of cervical cancer screening in 55 low- and middle-income countries","volume":"324","author":"Lemp","year":"2020","journal-title":"JAMA [Internet]."},{"key":"10.1016\/j.vaccine.2022.08.020_b0085","unstructured":"The World Bank. Prevalence of HIV, total (% of population ages 15-49) \u2013 Sub-Saharan Africa; 2020."},{"issue":"10224","key":"10.1016\/j.vaccine.2022.08.020_b0090","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0140-6736(20)30157-4","article-title":"Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries","volume":"395","author":"Canfell","year":"2020","journal-title":"Lancet [Internet]."},{"key":"10.1016\/j.vaccine.2022.08.020_b0095","doi-asserted-by":"crossref","unstructured":"Schiller J, Lowy D. Explanations for the high potency of HPV prophylactic vaccines. Vaccine [Internet]. 2018\/01\/08. 2018;36(32 Pt A):4768\u201373. <https:\/\/pubmed.ncbi.nlm.nih.gov\/29325819>.","DOI":"10.1016\/j.vaccine.2017.12.079"},{"key":"10.1016\/j.vaccine.2022.08.020_b0100","doi-asserted-by":"crossref","unstructured":"Falcaro M, Casta\u00f1on A, Ndlela B, Checchi M, Soldan K, Lopez-Bernal J, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet [Internet] 2021;398(10316):2084\u201392. doi:10.1016\/S0140-6736(21)02178-4.","DOI":"10.1016\/S0140-6736(21)02178-4"},{"key":"10.1016\/j.vaccine.2022.08.020_b0105","doi-asserted-by":"crossref","unstructured":"Lei J, Ploner A, Elfstr\u00f6m KM, Wang J, Roth A, Fang F, et al. HPV Vaccination and the risk of invasive cervical cancer. New England J Med [Int] 2020;383(14):1340\u20138. doi: 10.1056\/NEJMoa1917338.","DOI":"10.1056\/NEJMoa1917338"},{"key":"10.1016\/j.vaccine.2022.08.020_b0110","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2334-11-13","article-title":"Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis","volume":"11","author":"Lu","year":"2011","journal-title":"BMC Infect Dis"},{"issue":"46","key":"10.1016\/j.vaccine.2022.08.020_b0115","doi-asserted-by":"crossref","first-page":"8279","DOI":"10.1016\/j.vaccine.2011.08.106","article-title":"Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink","volume":"29","author":"Gee","year":"2011","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2022.08.020_b0120","doi-asserted-by":"crossref","first-page":"e1335","DOI":"10.1016\/S2214-109X(20)30277-1","article-title":"Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis","volume":"8","author":"Zou","year":"2020","journal-title":"Lancet Glob Health [Internet]"},{"key":"10.1016\/j.vaccine.2022.08.020_b0125","doi-asserted-by":"crossref","unstructured":"Malag\u00f3n T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Diseases [Internet] 2012;12(10):781\u20139. doi:10.1016\/S1473-3099(12)70187-1.","DOI":"10.1016\/S1473-3099(12)70187-1"},{"key":"10.1016\/j.vaccine.2022.08.020_b0130","doi-asserted-by":"crossref","unstructured":"WHO position on HPV vaccines. Vaccine 2009;27(52):7236\u20137.","DOI":"10.1016\/j.vaccine.2009.05.019"},{"issue":"43","key":"10.1016\/j.vaccine.2022.08.020_b0135","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.1016\/j.vaccine.2017.05.069","article-title":"WHO position paper, May 2017-recommendations","volume":"35","author":"Human papillomavirus vaccines","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.08.020_b0140","unstructured":"The World Health Organisation. WHO HPV Vaccine Dashboard."},{"key":"10.1016\/j.vaccine.2022.08.020_b0145","doi-asserted-by":"crossref","unstructured":"Drolet M, B\u00e9nard \u00c9, P\u00e9rez N, Brisson M, Ali H, Boily MC, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet [Internet]. 2019;394(10197):497\u2013509. doi:10.1016\/S0140-6736(19)30298-3.","DOI":"10.1016\/S0140-6736(19)30298-3"},{"issue":"10","key":"10.1016\/j.vaccine.2022.08.020_b0150","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1093\/infdis\/jiy075","article-title":"Very low prevalence of vaccine human papillomavirus types among 18- to 35-year old australian women 9 years following implementation of vaccination","volume":"217","author":"Machalek","year":"2018","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2022.08.020_b0155","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0029-7844(97)00695-9","article-title":"The history of the Papanicolaou smear and the odyssey of George and Andromache Papanicolaou","volume":"91","author":"Vilos","year":"1998","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.020_b0160","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1468-0009.2011.00652.x","article-title":"Cervical cancer screening in the United States and the Netherlands: a tale of two countries","volume":"90","author":"Habbema","year":"2012","journal-title":"Milbank Q"},{"key":"10.1016\/j.vaccine.2022.08.020_b0165","doi-asserted-by":"crossref","unstructured":"Denny L, Kuhn L, Hu CC, Tsai WY, Wright TC. Human Papillomavirus\u2013based cervical cancer prevention: long-term results of a randomized screening trial. JNCI: J Natl Cancer Inst [Internet] 2010;102(20):1557\u201367. doi:10.1093\/jnci\/djq342.","DOI":"10.1093\/jnci\/djq342"},{"key":"10.1016\/j.vaccine.2022.08.020_b0170","unstructured":"The World Health Organisation. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition. Geneva; 2021."},{"issue":"10167","key":"10.1016\/j.vaccine.2022.08.020_b0175","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0140-6736(18)32470-X","article-title":"Cervical cancer","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.08.020_b0180","doi-asserted-by":"crossref","unstructured":"Yao G, Qiu J, Zhu F, Wang X. Survival of patients with cervical cancer treated with definitive radiotherapy or concurrent chemoradiotherapy according to histological subtype: a systematic review and meta-analysis [Internet]. Vol. 9, Frontiers in Medicine; 2022. <https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2022.843262>.","DOI":"10.3389\/fmed.2022.843262"},{"issue":"4","key":"10.1016\/j.vaccine.2022.08.020_b0185","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.4049\/jimmunol.1800219","article-title":"A prime-pull-amplify vaccination strategy to maximize induction of circulating and genital-resident intraepithelial CD8(+) memory T cells","volume":"202","author":"\u00c7uburu","year":"2019","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2022.08.020_b0190","doi-asserted-by":"crossref","first-page":"106399","DOI":"10.1016\/j.ypmed.2020.106399","article-title":"HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010\u20132019","volume":"144","author":"Bruni","year":"2021","journal-title":"Preventive Medicine [Internet]"},{"key":"10.1016\/j.vaccine.2022.08.020_b0195","unstructured":"The World Health Organisation. WHO Immunization coverage [Internet]; 2021 [cited 2022 May 19]. <https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/immunization-coverage>."},{"key":"10.1016\/j.vaccine.2022.08.020_b0200","unstructured":"Bruni L, G A, B S, M M, JJ C, D G, et al. ICO\/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Africa. Summary Report 22 October 2021."},{"key":"10.1016\/j.vaccine.2022.08.020_b0205","doi-asserted-by":"crossref","unstructured":"Amponsah-Dacosta E, Blose N, Nkwinika VV, Chepkurui V. Human papillomavirus vaccination in south africa: programmatic challenges and opportunities for integration with other adolescent health services? [Internet]. Vol. 10, Frontiers in Public Health; 2022. <https:\/\/www.frontiersin.org\/article\/10.3389\/fpubh.2022.799984>.","DOI":"10.3389\/fpubh.2022.799984"},{"key":"10.1016\/j.vaccine.2022.08.020_b0210","doi-asserted-by":"crossref","unstructured":"Wong LP, Han L, Li H, Zhao J, Zhao Q, Zimet GD. Current issues facing the introduction of human papillomavirus vaccine in China and future prospects. Human Vacc Immunother [Internet]. 2019;15(7\u20138):1533\u201340. doi:10.1080\/21645515.2019.1611157.","DOI":"10.1080\/21645515.2019.1611157"},{"key":"10.1016\/j.vaccine.2022.08.020_b0215","unstructured":"UNICEF. The World Health Organisation. Progress and Challenges with Sustaining and Advancing Immunization Coverage During the COVID-19 Pandemic; 2021."},{"key":"10.1016\/j.vaccine.2022.08.020_b0220","unstructured":"The World Health Organisation. One-dose Human Papillomavirus (HPV) vaccine offers solid protection against cervical cancer [Internet]. <https:\/\/www.who.int\/news\/item\/11-04-2022-one-dose-human-papillomavirus-(hpv)-vaccine-offers-solid-protection-against-cervical-cancer#:\u223c:text=SAGE recommends updating dose schedules,for women older than 21>."},{"key":"10.1016\/j.vaccine.2022.08.020_b0225","doi-asserted-by":"crossref","unstructured":"Barnabas R v, Brown ER, Onono M, Bukusi EA, Njoroge B, Winer RL, et al. Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE Study): study protocol for a randomized controlled trial. Trials [Internet]. 2021;22(1):661. doi: 10.1186\/s13063-021-05608-8.","DOI":"10.1186\/s13063-021-05608-8"},{"key":"10.1016\/j.vaccine.2022.08.020_b0230","doi-asserted-by":"crossref","DOI":"10.1200\/GO.22.00051","article-title":"Lessons learnt from pilot cervical cancer screening and treatment programmes integrated to routine primary health care services in Benin, Cote d\u2019Ivoire and Senegal","author":"Selmouni","year":"2022","journal-title":"J Glob Oncol"},{"key":"10.1016\/j.vaccine.2022.08.020_b0235","doi-asserted-by":"crossref","unstructured":"Maza M, Schocken CM, Bergman KL, Randall TC, Cremer ML. Cervical precancer treatment in low- and middle-income countries: a technology overview. J Glob Oncol [Internet] 2016;3(4):400\u20138. Available from: 10.1200\/JGO.2016.003731.","DOI":"10.1200\/JGO.2016.003731"},{"key":"10.1016\/j.vaccine.2022.08.020_b0240","doi-asserted-by":"crossref","unstructured":"Castle PE, Einstein MH, Sahasrabuddhe VV. Cervical cancer prevention and control in women living with human immunodeficiency virus. CA: A Cancer J Clin [Internet]. 2021;71(6):505\u201326. doi:10.3322\/caac.21696.","DOI":"10.3322\/caac.21696"},{"key":"10.1016\/j.vaccine.2022.08.020_b0245","doi-asserted-by":"crossref","first-page":"200238","DOI":"10.1016\/j.tvr.2022.200238","article-title":"Cervical cancer therapies: current challenges and future perspectives","volume":"13","author":"Burmeister","year":"2022","journal-title":"Tumour Virus Res [Internet]"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.020_b0250","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1186\/s12885-017-3786-3","article-title":"Estimating the value of point-of-care HPV testing in three low- and middle-income countries: a modeling study","volume":"17","author":"Campos","year":"2017","journal-title":"BMC Cancer [Internet]"},{"key":"10.1016\/j.vaccine.2022.08.020_b0255","doi-asserted-by":"crossref","unstructured":"Nguyen DTN, Simms KT, Keane A, Mola G, Bolnga JW, Kuk J, et al. Towards the elimination of cervical cancer in low-income and lower-middle-income countries: modelled evaluation of the effectiveness and cost-effectiveness of point-of-care HPV self-collected screening and treatment in Papua New Guinea. BMJ Global Health [Internet]. 202;7(3):e007380. <http:\/\/gh.bmj.com\/content\/7\/3\/e007380.abstract>.","DOI":"10.1136\/bmjgh-2021-007380"},{"key":"10.1016\/j.vaccine.2022.08.020_b0260","doi-asserted-by":"crossref","unstructured":"Kreimer AR, Herrero R, Sampson JN, Porras C, Lowy DR, Schiller JT, et al. Evidence for single-dose protection by the bivalent HPV vaccine-Review of the Costa Rica HPV vaccine trial and future research studies. Vaccine [Internet]. 2018\/02\/01. 2018 Aug 6;36(32 Pt A):4774\u201382. <https:\/\/pubmed.ncbi.nlm.nih.gov\/29366703>.","DOI":"10.1016\/j.vaccine.2017.12.078"},{"issue":"9590","key":"10.1016\/j.vaccine.2022.08.020_b0265","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0140-6736(07)61416-0","article-title":"Human papillomavirus and cervical cancer","volume":"370","author":"Schiffman","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.vaccine.2022.08.020_b0270","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type","volume":"141","author":"de Martel","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2022.08.020_b0275","unstructured":"The World Health Organisation, IVIR-AC. Meeting of the Advisory Committee on Immunization and Vaccinesrelated Implementation Research (IVIR-AC) [Internet]. Geneva; 2022. <https:\/\/terrance.who.int\/mediacentre\/data\/sage\/220225-IVIR-AC-Pink-Book-March-2022.pdf>."},{"key":"10.1016\/j.vaccine.2022.08.020_b0280","unstructured":"The World Health Organisation. WHO Cervical Cancer Prevention and Control Costing (C4P) Tool."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22009999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22009999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T20:21:30Z","timestamp":1786220490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22009999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":56,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0264410X22009999"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.08.020","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021\u2014March 2022","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 World Health Organization. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}